Ebr Systems DRC receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | EBR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEBRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.3x | 8.8x | −0.3x | |
PEG Ratio | 0.11 | 0.01 | 0.00 | |
Price/Book | 2.0x | 2.2x | 2.6x | |
Price / LTM Sales | 21.5x | 2.6x | 3.0x | |
Upside (Analyst Target) | - | 34.7% | 59.8% | |
Fair Value Upside | Unlock | 24.2% | 7.1% | Unlock |
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It offers WiSE cardiac resynchronization therapy system, an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads; and stimulation of the left ventricular endocardium for cardiac resynchronization therapy (SOLVE-CRT), an investigational device exemption. The company was incorporated in 2003 and is headquartered in Sunnyvale, California.